Stockreport

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Inc.  (NGNE) 
PDF Single trial to support future BLA submission for NGN-401 in patients ages = 3 yearsRapid trial execution underway with 12 of 13 clinical sites initiatedExpect to comple [Read more]